Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the conversion of arachidonic acid into prostaglandins. Lower prostaglandin levels decrease inflammation, lower fever, and reduce the sensitisation of pain receptors, producing analgesic and antipyretic effects.

The specific dose and infusion rate of Ibuprofen B. Braun are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other clinical factors. Healthcare professionals should follow local prescribing guidelines and the product’s prescribing information.

The pregnancy category for this intravenous ibuprofen product is not established. Generally, NSAIDs are avoided in the third trimester because of potential fetal complications, and they should be used during pregnancy only when the benefit justifies the risk. Breastfeeding mothers should consult a physician before use.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Compared with oral NSAIDs, the intravenous form offers faster onset and more predictable plasma levels, which is advantageous in acute care. Unlike opioids, ibuprofen provides analgesia without respiratory depression, but it shares the typical NSAID risks of gastrointestinal bleeding, renal effects, and platelet inhibition.

The product must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before administration, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required by the infusion protocol.

Ibuprofen B. Braun is given by intravenous infusion. The healthcare professional selects an appropriate infusion set, dilutes the solution if required by the label, and administers it over the recommended time period, usually under continuous monitoring for adverse reactions.

Serious risks include anaphylactic reactions, acute renal impairment, and gastrointestinal bleeding or ulceration. Patients should be monitored for signs of allergic response, sudden changes in urine output, or unexplained abdominal pain or bleeding during and after infusion.

Contraindications include patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, uncontrolled heart failure, and those in the third trimester of pregnancy unless the benefit outweighs the risk.